CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2024

Nov 30, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2024-11-27

Reporting Person: Harper Molly (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-11-27	Common stock, par value $0.001 per share	M	17500	$5.78	Acquired	17500	Direct
2024-11-27	Common stock, par value $0.001 per share	S	17500	$22.00	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-11-27	Options to purchase common stock	$5.78	M	17500	Disposed	2028-06-29	Common Stock (17500)	Direct

Footnotes

F1: Shares were sold on the open market for personal reasons and to fund the exercise price of the stock options, and not as a result of any disagreement with the Company.

F2: Options vested in three annual tranches beginning on June 29, 2022.